Exonate
Exonate is a biotechnology company focused on treatment options for patients with retinal vascular diseases. Their lead asset, EXN407, is a topical therapy for conditions such as diabetic retinopathy and diabetic macular oedema, which is entering Phase IIb clinical trials in 2024.
- Topical therapy for diabetic retinopathy
- Topical therapy for diabetic macular oedema
- Small molecule drugs for retinal vascular diseases
Locations
Competitors
Harness Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases through innovative RNA translation methodologies.
Company Details
Exonate is operated by Exonate Limited and is a Active company incorporated on 5 December 2013 with the registered office located in Cambridge, Cambridgeshire. Exonate Limited was registered 11 years ago.
Status
Active
Size
Micro
Directors
7
Age
11 years old
Employees
14
Turnover
Unreported
Total Assets
£2.54M
Cash in Bank
£2.01M
Total Liabilities
-£6.52M
Teams
10
6
2
2
2
Chief Executive Officer
Co-founder • Joined Dec 2013
Non Executive Director • Joined Nov 2018
Chief Operating Officer • Joined Jun 2019
Finance Manager • Joined Mar 2017
Managing Director • Joined Apr 2017
Managing Director • Joined Jun 2016
Head Of Biology • Joined Apr 2017
Senior Scientist • Joined Dec 2016
Commercial Advisor • Joined Jan 2013
Chief Executive Officer
Co-founder • Joined Dec 2013
Non Executive Director • Joined Nov 2018
Chief Operating Officer • Joined Jun 2019
Managing Director • Joined Apr 2017
Managing Director • Joined Jun 2016
Finance Manager • Joined Mar 2017
Commercial Advisor • Joined Jan 2013
Head Of Biology • Joined Apr 2017
Senior Scientist • Joined Dec 2016
Head Of Biology • Joined Apr 2017
Senior Scientist • Joined Dec 2016